Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radioactive antibody targets cancer before stem cell transplant in High-Risk leukemia trial

NCT ID NCT03670966

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a radioactive antibody (211At-BC8-B10) that seeks out and attacks cancer cells, followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has returned or not responded to treatment. The goal is to find the best dose that safely destroys cancer while allowing the new stem cells to grow. After the transplant, patients must take medications to prevent graft-versus-host disease, so this is a disease-control approach, not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute lymphoblastic leukemia acute monocytic leukemia acute myeloid leukemia acute myeloid leukemia with multilineage dysplasia chronic myelomonocytic leukemia hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm lymphoid leukemia mixed phenotype acute leukemia myelodysplastic syndrome with excess blasts Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME ACUTE MYELOID LEUKEMIA IN REMISSION CHRONIC MYELOMONOCYTIC LEUKEMIA HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA REFRACTORY MIXED PHENOTYPE ACUTE LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.